These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37718933)

  • 21. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
    Arai T; Takahashi H; Seko Y; Toyoda H; Hayashi H; Yamaguchi K; Iwaki M; Yoneda M; Shima T; Fujii H; Morishita A; Kawata K; Tomita K; Kawanaka M; Yoshida Y; Ikegami T; Notsumata K; Oeda S; Atsukawa M; Kamada Y; Sumida Y; Fukushima H; Miyoshi E; Aishima S; Okanoue T; Itoh Y; Nakajima A;
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):789-797.e8. PubMed ID: 38048934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.
    Srivastava A; Jong S; Gola A; Gailer R; Morgan S; Sennett K; Tanwar S; Pizzo E; O'Beirne J; Tsochatzis E; Parkes J; Rosenberg W
    BMC Gastroenterol; 2019 Jul; 19(1):122. PubMed ID: 31296161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.
    Younossi ZM; Stepanova M; Felix S; Jeffers T; Younossi E; Goodman Z; Racila A; Lam BP; Henry L
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1417-1422. PubMed ID: 36967586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of the liver in type 2 diabetes: important but unfeasible?
    Qadri S; Yki-Järvinen H
    Diabetologia; 2024 Jun; 67(6):961-973. PubMed ID: 38334817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD.
    Hegmar H; Wiggers T; Nasr P; Vessby J; Kechagias S; Nyhlin N; Marschall HU; Borssén ÅD; Strandberg R; Karsdal M; Leeming DJ; Ekstedt M; Hagström H
    J Intern Med; 2024 Aug; 296(2):177-186. PubMed ID: 38959258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive tests for nonalcoholic fatty liver disease in a multi-ethnic population: The HELIUS study.
    van Dijk AM; Vali Y; Mak AL; Galenkamp H; Nieuwdorp M; van den Born BJ; Holleboom AG
    Hepatol Commun; 2023 Jan; 7(1):e2109. PubMed ID: 36333949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients.
    Dabbah S; Ben Yakov G; Kaufmann MI; Cohen-Ezra O; Likhter M; Davidov Y; Ben Ari Z
    Minerva Gastroenterol (Torino); 2024 Sep; 70(3):322-331. PubMed ID: 37889111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
    Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
    Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis.
    Babakinejad P; Lapsley R; Forster L; McPherson S; Pearce MS; Reynolds NJ; Slack E; Weatherhead SC; Hampton PJ
    Br J Dermatol; 2024 Jul; 191(2):275-283. PubMed ID: 38366967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.